Ariad Pharmaceuticals, Inc. Announces Commercial Agreement For Iclusig (Ponatinib) In Israel

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass. & PETACH TIKVA, Israel--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Medison Pharma Ltd, Israel’s leading international marketing group for innovative pharmaceuticals, today announced that ARIAD has granted Medison exclusive rights to commercialize Iclusig® (ponatinib) in Israel in patients with Philadelphia-positive (Ph+) leukemias.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC